Molecular characterization of the β-amyloid(4-10) epitope of plaque specific Aβ antibodies by affinity-mass spectrometry using alanine site mutation
Related Experiment Video
Updated: Feb 15, 2026

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Raluca Ștefănescu1,2, Loredana Lupu3,4, Marilena Manea1,5
1Department of Chemistry, Laboratory of Analytical Chemistry, University of Konstanz, 78457, Konstanz, Germany.
Abstract:
Alzheimer disease is a neurodegenerative disease affecting an increasing number of patients worldwide. Current therapeutic strategies are directed to molecules capable to block the aggregation of the β-amyloid(1-42) (Aβ) peptide and its shorter naturally occurring peptide fragments into toxic oligomers and amyloid fibrils. Aβ-specific antibodies have been recently developed as powerful antiaggregation tools. The identification and functional characterization of the epitope structures of Aβ antibodies contributes to the elucidation of their mechanism of action in the human organism. In previous studies, the Aβ(4-10) peptide has been identified as an epitope for the polyclonal anti-Aβ(1-42) antibody that has been shown capable to reduce amyloid deposition in a transgenic Alzheimer disease mouse model. To determine the functional significance of the amino acid residues involved in binding to the antibody, we report here the effects of alanine single-site mutations within the Aβ-epitope sequence on the antigen-antibody interaction. Specific identification of the essential affinity preserving mutant peptides was obtained by exposing a Sepharose-immobilized antibody column to an equimolar mixture of mutant peptides, followed by analysis of bound peptides using high-resolution MALDI-Fourier transform-Ion Cyclotron Resonance mass spectrometry. For the polyclonal antibody, affinity was preserved in the H6A, D7A, S8A, and G9A mutants but was lost in the F4, R5, and Y10 mutants, indicating these residues as essential amino acids for binding. Enzyme-linked immunosorbent assays confirmed the binding differences of the mutant peptides to the polyclonal antibody. In contrast, the mass spectrometric analysis of the mutant Aβ(4-10) peptides upon affinity binding to a monoclonal anti-Aβ(1-17) antibody showed complete loss of binding by Ala-site mutation of any residue of the Aβ(4-10) epitope. Surface plasmon resonance affinity determination of wild-type Aβ(1-17) to the monoclonal Aβ antibody provided a binding constant KD in the low nanomolar range. These results provide valuable information in the elucidation of the binding mechanism and the development of Aβ-specific antibodies with improved therapeutic efficacy.
Insights
Researchers identified key amino acid residues in the Alzheimer's disease-related beta-amyloid (Aβ) peptide that are crucial for antibody binding. This finding aids in developing more effective Aβ-targeting therapies for Alzheimer's disease.
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Alzheimer disease is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) peptide aggregation.
- Aβ-specific antibodies are promising therapeutic tools to inhibit Aβ aggregation and reduce amyloid deposition.
- Understanding the epitope structure of Aβ antibodies is crucial for elucidating their mechanism of action.
Purpose of the Study:
- To functionally characterize the amino acid residues within the Aβ(4-10) epitope essential for antibody binding.
- To investigate the impact of alanine single-site mutations on antigen-antibody interactions.
- To provide insights for the development of improved Aβ-specific therapeutic antibodies.
Main Methods:
- Alanine scanning mutagenesis was performed on the Aβ(4-10) peptide epitope.
- Affinity purification using immobilized antibodies coupled with mass spectrometry (MALDI-FT-ICR-MS) to identify binding-competent peptides.
- Enzyme-linked immunosorbent assays (ELISA) and Surface Plasmon Resonance (SPR) to confirm binding affinities.
Main Results:
- For a polyclonal anti-Aβ(1-42) antibody, residues F4, R5, and Y10 in the Aβ(4-10) epitope were identified as essential for binding, while H6, D7, S8, and G9 were less critical.
- A monoclonal anti-Aβ(1-17) antibody showed a complete loss of binding to the Aβ(4-10) epitope upon alanine substitution of any residue, indicating a broader epitope recognition.
- SPR analysis revealed a low nanomolar binding constant (KD) for the wild-type Aβ(1-17) peptide and the monoclonal antibody.
Conclusions:
- Specific amino acid residues within the Aβ(4-10) sequence play differential roles in binding to various anti-Aβ antibodies.
- These findings enhance the understanding of Aβ-antibody interactions and epitope mapping.
- The results are valuable for the rational design and optimization of Aβ-specific antibodies for Alzheimer disease therapeutics.
Related Concept Videos
Mass Spectrometry: Molecular Fragmentation Overview
One type of fragmentation pattern is the cleavage of a single bond in the molecular ion. The cleavage leads to a radical and a cation. The cleavage can occur at...
Affinity and Avidity
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Mass Spectrometry: Overview
Tandem Mass Spectrometry
Mass Spectrometry of Amines

